Cargando…
PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge
BACKGROUND: Inhaled allergen challenges are often used to evaluate novel asthma treatments in early phase clinical trials. Current novel therapeutic targets in asthma include phosphoinositide 3-kinases (PI3K) delta and gamma, p38 mitogen-activated protein kinase (p38) and Janus kinase/Signal Transdu...
Autores principales: | Southworth, Thomas, Mason, Sarah, Bell, Alan, Ramis, Isabel, Calbet, Marta, Domenech, Anna, Prats, Neus, Miralpeix, Montserrat, Singh, Dave |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896031/ https://www.ncbi.nlm.nih.gov/pubmed/29651336 http://dx.doi.org/10.1186/s40364-018-0128-9 |
Ejemplares similares
-
Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016) -
The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro
por: Milara, Javier, et al.
Publicado: (2022) -
Zhike pingchuan granules improve bronchial asthma by regulating the IL-6/JAK2/STAT3 pathway
por: Ren, Yumei, et al.
Publicado: (2021) -
Clinical Characteristics According to Sensitized Allergens in Adult Korean Patients With Bronchial Asthma
por: Jung, Jae Woo, et al.
Publicado: (2010) -
Segmental Bronchial Allergen Challenge Elicits Distinct Metabolic Phenotypes in Allergic Asthma
por: Zhu, Yanlong, et al.
Publicado: (2022)